Jinyu Bio-technology

Jinyu Bio-technology, established in 1993, stands as the preeminent animal vaccine manufacturer within China. Operating within the chemicals and manufacturing sectors, the firm maintains a dominant market position by providing a comprehensive portfolio of vaccines tailored for ruminants, swine, and poultry. As the leading producer of Foot-and-Mouth Disease (FMD) vaccines in the region, Jinyu Bio-technology distinguishes itself as one of the few domestic entities whose products consistently adhere to rigorous international quality standards. The company’s commitment to innovation is evidenced by its recognition as the 2016 Best Company in Asia and Australasia by Animal Pharm.

The company’s operational infrastructure is anchored by China’s uniquely designated national animal vaccine engineering laboratory and a high-containment BSL-3 facility. These technical assets enable the development of a sophisticated pipeline of advanced animal health solutions. Jinyu Bio-technology has significantly expanded its global footprint, successfully exporting vaccines to markets including Mongolia, Bangladesh, and Egypt. Furthermore, the firm is actively scaling its production capabilities through the Jinyu International Biotechnology Industrial Park in Hohhot, a massive 110-acre facility designed to serve as a primary R&D and manufacturing hub for future growth.

With a workforce of 1,000-5,000 employees, Jinyu Bio-technology continues to drive industry advancement through sustained investment in biotechnology. The company reported annual revenue of $228.0M, reflecting a consistent growth trajectory that has exceeded 30% annually since 2012. Meet Jinyu Bio-technology's team to learn more about the leadership driving these strategic initiatives and the technical expertise behind their vaccine development programs.